CJC/IPA Protocol vs Retatrutide
Well Studied vs Extensively Studied
monitor Mechanism-based · 47% Both CJC/IPA Protocol and Retatrutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
CJC/IPA Protocol Retatrutide
Weight N/A 4,731.33 Da
Half-life — ~6 days
Chain N/A 39 amino acids
Type Peptide combination (GHRH analog + GHS) Triple GLP-1/GIP/glucagon agonist
Key Benefits
CJC/IPA Protocol
01 Sustained GH elevation (6-8 days from CJC-1295)
02 Selective pulsatile release without cortisol suppression
03 Complementary dual-pathway optimization
04 Preservation of natural GH rhythm
05 Enhanced muscle protein synthesis and recovery
Retatrutide
01 Superior weight loss (24.2% at 48 weeks)
02 Improved glycemic control (HbA1c reduction up to 2.16%)
03 Enhanced cardiovascular benefits
04 Hepatic fat reduction (up to 82%)
05 Triple mechanism addresses obesity through multiple pathways
Dosing Protocols
CJC/IPA Protocol
200-300mcg of each peptide (CJC-1295 and Ipamorelin) / Once daily, preferably in the evening
General Health Optimization 200mcg each (0.2mL if 1mg/mL) Once daily
Performance Enhancement 250mcg each (0.25mL if 1mg/mL) Once daily
Recovery Optimization 300mcg each (0.3mL if 1mg/mL) Once daily
Conservative Approach 150mcg each (0.15mL if 1mg/mL) 5 days per week
Retatrutide
0.5mg starting, titrate up to 8-12mg weekly / Once weekly (same day each week)
Starting Dose (Week 1-4) 0.5mg Once weekly
Low Maintenance (Week 4-8) 1mg Once weekly
Escalation (Week 8-12) 2mg Once weekly
Moderate (Week 12-16) 4mg Once weekly
Advanced (Week 16-20) 8mg Once weekly
Maximum Efficacy (Week 20+) 12mg Once weekly
Side Effects
CJC/IPA Protocol
Water retention and joint swelling
Carpal tunnel syndrome (numbness/tingling)
Mild blood glucose elevation
Injection site irritation with improper rotation
Retatrutide
Gastrointestinal effects (nausea, vomiting, diarrhea)—typically mild to moderate
Heart rate increases—common especially in first 24 weeks
Appetite suppression
Mild dehydration
Contraindications
Cancer history or active malignancy
Severe diabetes requiring tight glucose control
Carpal tunnel syndrome or nerve compression disorders
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome
Severe renal impairment
Research Evidence
CJC/IPA Protocol Retatrutide
Status Well Studied Extensively Studied
References 4 studies 6 studies
Latest June 2024 2025-10
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.